Patients with chronic symptomatic heart failure with a known reduced left ventricular ejection fraction (LVEF ≤40%) were excluded from the trial because these patients had an absolute indication for treatment with an SGLT2 inhibitor. The gene discussed is SLC5A2; the disease is heart failure.